Ming Hsieh - Fulgent Genetics Chairman of the Board and Presidentident, CEO
| FLGT Stock | USD 20.75 0.03 0.14% |
Chairman
Mr. Ming Hsieh is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Hsieh is Chairman of our Board of Directors, President and Chief Executive Officer. Prior to founding Fulgent, Mr. Hsieh served as Chief Executive Officer, President and Chairman of the board of directors of Cogent, Inc., or Cogent, a biometric identification services and products company he cofounded in 1990, which was acquired by 3M in 2010. Prior to his tenure at Cogent, Mr. Hsieh founded and served as Vice President of AMAX Technology from 1987 to 1990. Mr. Hsieh currently serves on the board of directors of Fortinet, Inc., a network security company traded on the NASDAQ Global Select Market under the symbol FTNT. Mr. Hsieh received a B.S.E.E. from USC in 1983 and an M.S.E.E. from USC in 1984, as well as honorary doctoral degrees from USC in 2010 and the University of West Virginia in 2011. Mr. Hsieh has served as a trustee at USC since 2007 and at Fudan University in China since 2011. In 2015, Mr. Hsieh was elected to the National Academy of Engineering
| Age | 68 |
| Address | 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 |
| Phone | 626-350-0537 |
| Web | https://www.fulgentgenetics.com |
Ming Hsieh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ming Hsieh against Fulgent Genetics stock is an integral part of due diligence when investing in Fulgent Genetics. Ming Hsieh insider activity provides valuable insight into whether Fulgent Genetics is net buyers or sellers over its current business cycle. Note, Fulgent Genetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fulgent Genetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ming Hsieh over a month ago Disposition of 8667 shares by Ming Hsieh of Fulgent Genetics at 24.06 subject to Rule 16b-3 |
Fulgent Genetics Management Efficiency
The company has return on total asset (ROA) of (0.0347) % which means that it has lost $0.0347 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1458) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to drop to -0.07 in 2024. At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 70.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 49.4 M in 2024.Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Jay Flatley | Illumina | 65 | |
| Steven Rales | Danaher | 73 | |
| Christopher OConnell | Waters | 51 | |
| Jim Manzi | Thermo Fisher Scientific | 68 | |
| Kevin Conroy | EXACT Sciences | 58 | |
| James Cullen | Agilent Technologies | 72 | |
| James Foster | Charles River Laboratories | 70 | |
| Mitchell Rales | Danaher | 67 | |
| Michael Goldberg | Caredx Inc | 60 | |
| William Rastetter | Illumina | 66 | |
| Boon Koh | Agilent Technologies | 70 | |
| Matthew Rabinowitz | Natera Inc | 51 | |
| Douglas Berthiaume | Waters | 66 | |
| Flemming Ornskov | Waters | 62 | |
| Robert Spoerry | Mettler Toledo International | 65 | |
| Thomas Lynch | Thermo Fisher Scientific | 66 | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0347 |
Fulgent Genetics Leadership Team
Elected by the shareholders, the Fulgent Genetics' board of directors comprises two types of representatives: Fulgent Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fulgent. The board's role is to monitor Fulgent Genetics' management team and ensure that shareholders' interests are well served. Fulgent Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fulgent Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Doreen Ng, VP Office | ||
| Ming Hsieh, Chairman of the Board and Presidentident, CEO | ||
| James Mulay, Director | ||
| Linda Marsh, Director | ||
| Lawrence MD, Chief Officer | ||
| Brandon Perthuis, Chief Officer | ||
| Jian Xie, COO President | ||
| Jakub Sram, Vice Sales | ||
| John Bolger, Director | ||
| Hanlin Gao, Lab Director and Chief Scientific Officer | ||
| DABMG FACMG, Chief Director | ||
| Paul Kim, Chief Officer | ||
| Natalie Prescott, General Officer | ||
| Ray Yin, President Pharma | ||
| Yun Yen, Director | ||
| Ellen Tsui, Vice Resources |
Fulgent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fulgent Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0347 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 205.55 M | ||||
| Shares Outstanding | 29.9 M | ||||
| Shares Owned By Insiders | 32.58 % | ||||
| Shares Owned By Institutions | 49.29 % | ||||
| Number Of Shares Shorted | 603.98 K | ||||
| Price To Earning | 3.95 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.